BACKGROUND: Extracorporeal support with single-pass albumin dialysis (SPAD) may remove protein-bound toxins in acute liver failure. We evaluated the clinical, physiological and laboratory parameters of SPAD in acetaminophen-induced acute liver failure (AALF). METHODS: Retrospective case-control studies of AALF patients were used. RESULTS: We identified 13 AALF patients (6 SPAD-treated, 7 controls). The average age was 38 years, 92% were female, none had cirrhosis and the Model for End-Stage Liver Disease (MELD) scores were 43. Eleven patients (85%) fulfilled the King's College criteria for a liver transplant. SPAD-treated patients received 21 sessions (total: 147 h, mean 3.5 runs or 24.5 h/patient). There were no complications. No significant changes in clinical, physiological or biochemical parameters occurred during SPAD. Compared with the controls, there were no significant differences in ICU or 1-year survival, liver recovery or referral for a liver transplant. CONCLUSION: SPAD was well-tolerated in AALF; however, it was not associated with differences in clinical outcomes. While SPAD may be an adjuvant supportive therapy in AALF, prospective trials are needed. Copyright 2009 S. Karger AG, Basel.
BACKGROUND: Extracorporeal support with single-pass albumin dialysis (SPAD) may remove protein-bound toxins in acute liver failure. We evaluated the clinical, physiological and laboratory parameters of SPAD in acetaminophen-induced acute liver failure (AALF). METHODS: Retrospective case-control studies of AALF patients were used. RESULTS: We identified 13 AALF patients (6 SPAD-treated, 7 controls). The average age was 38 years, 92% were female, none had cirrhosis and the Model for End-Stage Liver Disease (MELD) scores were 43. Eleven patients (85%) fulfilled the King's College criteria for a liver transplant. SPAD-treated patients received 21 sessions (total: 147 h, mean 3.5 runs or 24.5 h/patient). There were no complications. No significant changes in clinical, physiological or biochemical parameters occurred during SPAD. Compared with the controls, there were no significant differences in ICU or 1-year survival, liver recovery or referral for a liver transplant. CONCLUSION: SPAD was well-tolerated in AALF; however, it was not associated with differences in clinical outcomes. While SPAD may be an adjuvant supportive therapy in AALF, prospective trials are needed. Copyright 2009 S. Karger AG, Basel.
Authors: Mitra K Nadim; John A Kellum; Andrew Davenport; Florence Wong; Connie Davis; Neesh Pannu; Ashita Tolwani; Rinaldo Bellomo; Yuri S Genyk Journal: Crit Care Date: 2012-02-09 Impact factor: 9.097
Authors: Jenna Essink; Sydney Berg; Jaka Montange; Andrew Sankey; Veronica Taylor; Jeffrey Salomon Journal: J Investig Med High Impact Case Rep Date: 2022 Jan-Dec
Authors: Ahmed Al-Chalabi; Edouard Matevossian; Anne-K V Thaden; Peter Luppa; Albrecht Neiss; Tibor Schuster; Zejian Yang; Catherine Schreiber; Patrick Schimmel; Ewald Nairz; Aurel Perren; Peter Radermacher; Wolfgang Huber; Roland M Schmid; Bernhard Kreymann Journal: BMC Gastroenterol Date: 2013-05-13 Impact factor: 3.067